Moderna, Inc. Form 8-K Summary
Business Context and Reporting Period
Moderna, Inc. filed this Current Report on Form 8-K on January 12, 2026, to disclose preliminary financial information presented at the 44th Annual J.P. Morgan Healthcare Conference. The data pertains to the fiscal year ended December 31, 2025.
Key Financial Metrics
- Revenue: Approximately $1.9 billion (unaudited) for the fiscal year ended December 31, 2025.
- Operating Expenses: GAAP operating expenses expected to be between $5.0 billion and $5.2 billion (unaudited) for the fiscal year ended December 31, 2025.
- Liquidity: Cash, cash equivalents, and investments in marketable securities expected to be approximately $8.1 billion (unaudited) as of December 31, 2025.
- Profitability: The filing does not provide a clear value for net income or operating income, though the expense range implies a significant operating loss relative to revenue.
- Debt: The filing text does not provide a clear value for total debt or specific debt obligations.
Material Changes and Outlook
The filing does not provide comparative data for the prior period (2024) to quantify material changes in revenue or expenses. Management commentary is limited to the preliminary nature of the figures, noting that the audit for the year ended December 31, 2025, is ongoing and could result in changes to the reported information.
Risks and Contingencies
The primary risk noted is that the financial information is unaudited and preliminary. The final audited financial statements may differ from the figures presented in this report. No other specific risks, contingencies, or unusual items were detailed in the text of this filing.
Investor Verification Checklist
- Verify the final audited revenue and expense figures once the 2025 annual report is filed.
- Confirm the exact composition of the $8.1 billion liquidity position (cash vs. marketable securities).
- Review the upcoming audited financial statements for any adjustments to the preliminary $1.9 billion revenue estimate.
- Assess the impact of the projected operating loss (revenue of $1.9B vs. expenses of $5.0B-$5.2B) on future cash burn rates.
